These data consistently revealed that MIR4435-2HG participated in the regulation of glutamine metabolism, and promoted the energy remodeling and malignant development of FH-deficient RCC, and GLS1 could be metabolically target for these tumors. The gene discussed is GLS; the disease is renal cell carcinoma.